Molina Healthcare, Inc. (MOH) Cash Flow Statement

Claims paid rose from $8.7 billion in 2024Q2 to $9.7 billion in 2026Q3, an increase of about 11.5%, while the prior income statement work showed revenue contracting 7.8% in that same latest period, a divergence suggesting medical outlays are settling faster than premium receivables are being collected. This may reflect redetermination-driven membership losses arriving alongside lagged state premium payments, though it could equally indicate that incurred medical costs are running ahead of earned premium. The persistence of negative operating cash flow in quarters that still produced positive net income implies the premium float is not currently offsetting claims disbursements, and investors should monitor whether the shortfall narrows as collections catch up.

The extreme dispersion in the OCF-to-net income ratio, spanning 77.29 in 2026Q1 and negative 4.18 in 2026Q3, suggests quarterly earnings quality is being driven substantially by accrual movements and payment timing rather than by a stable operating engine. This is directionally consistent with the prior finding that only 8% of 2026Q1 operating income converted to net income, pointing to material reserve and below-the-line accruals that the cash statement does not itemize. Given the reported 99.0% combined ratio, the absence of a dependable operating cash surplus may indicate that current-period medical costs are consuming nearly all cash premium before any cushion is retained.

A pattern in which investment sales repeatedly outpace purchases implies the portfolio is being used as a liquidity buffer when premium collections lag claims payments, rather than being built up from surplus underwriting cash. The 2026Q3 quarter is notable on this measure, with $619 million of purchases against $348 million of sales occurring simultaneously with negative $159 million of operating cash flow, a combination that appears to have drawn on existing balance sheet cash. Investors should treat continued net sales as a signal that float generation remains under pressure, while recognizing that reinvestment timing across a single quarter may distort the trend.

With dividends at zero across all ten quarters, the entirety of capital return has taken the form of repurchases, and roughly 3.7 times the cumulative operating cash surplus was returned to shareholders, implying the payout is being supported by portfolio sales and accumulated cash. Notably, the full $500 million quarterly repurchase pace continued through 2024Q4 and 2025Q3 despite negative operating cash flow in those periods, then effectively stopped in 2026Q2 and 2026Q3 with only $14 million in 2026Q1, a sequencing that may indicate management discipline in response to weak cash generation or, alternatively, a temporary constraint. The safety of the repurchase program should be judged against operating cash recovery rather than reported earnings, since the latter has repeatedly failed to convert.